

AMENDMENTS TO THE CLAIMS

a' 1. (currently amended) ~~Use of a clotting preventing agent in the production of a drug for administration in connection with~~ A method comprising transplantation of insulin producing cells in the form of isolating islets to a patients-patient with suffering from insulin dependent diabetes mellitus, (IDDM), wherein said isolated islets are coated with a clotting preventing agent, with the proviso that the isolated islets are not artificially encapsulated.

2. (currently amended) ~~Use~~ The method according to claim 1, wherein the preventing agent is an anticoagulant.

3. (currently amended) ~~Use~~ The method according to claim 2, wherein the anticoagulant is heparin or fractions or derivatives thereof.

4. (currently amended) ~~Use~~ The method according to claim 3, wherein islet cells are coated with heparin or fractions or derivatives thereof by preincubation of islets in a solution containing heparin or fractions or derivatives thereof.

5. (currently amended) Use The method according to claim 1, wherein the preventing agent is an inhibitor of platelet activation.

a1
Cont
6. (currently amended) Use The method according to claim 5, wherein the preventing agent is a RGD containing peptide or a monoclonal antibody which inhibits the interaction of platelet integrins with their specific ligands.

7. (currently amended) Use The method according to claim 5, wherein the preventing agent is a monoclonal antibody or a peptide directed against the Fc receptor on platelets.

8. (currently amended) Use The method according to any one of the ~~above~~ claims 1-7, wherein more than one clotting preventing agent is used.

9. (currently amended) Use The method according to any one of the ~~above~~ claims 1-7, wherein the preventing agent(s) is/are supplemented by an inhibitor of complement.

10. (currently amended) ~~Isolated cells comprising islets of Langerhans, characterized by being coated~~ A method for coating isolated cells, comprising coating islets of Langerhans cells with a heparin conjugate on the islet surface, with the proviso that the cells are not artificially encapsulated.

a¹
cont

11. (currently amended) A method for increasing survival of islet cells in connection with transplantation of insulin producing cells to patients with insulin dependent diabetes mellitus, (IDDM), comprising prevention of clotting, monitored as reduced generation of thrombin-~~antitrombin~~ antithrombin complex (TAT complex).
